Skip to main content
. 2026 May 13;20(1):2025-0153. doi: 10.5797/jnet.ra.2025-0153

Table 2. Overview of recent and ongoing main trials of MMAE for CSDH.

Trial name Country Size Completion Population Intervention Embolic agent Primary outcome Follow-up
MMAE + surgery vs. surgery
METRICS40) China 516 Dec-24 At least 1 risk factor for recurrence 1. MMAE + surgery vs. surgery
2. MMAE vs. atorvastatin
Not stated Repeat surgery or radiological 6 months
MEMBRANE (USA)42) USA 376 Mar-25 mRS score ≤3 1. MMAE + surgery vs. surgery
2. MMAE vs. conservative
TRUFILL n-BCA Repeat surgery or radiological 6 months
OTEMACS37) France 440 May-25 Symptoms and mRS score ≤3 1. MMAE + surgery vs. surgery
2. MMAE vs. conservative
Onyx Repeat surgery or radiological 3 months
LEADH43) France 550 Sep-26 CSDH >10 mm 1. MMAE + surgery vs. surgery
2. MMAE vs. conservative
Cyanoacrylates Symptomatic recurrence or repeat surgery or radiological 2, 6 months
STORMM41) Switzerland 180 Jan-27 Symptoms or failed conservative 1. MMAE + surgery vs. surgery
2. MMAE vs. conservative
Not stated Symptomatic recurrence or repeat surgery or radiological 6 months
ChiCTR200003935947) China 480 Mar-23 Symptoms MMAE + surgery vs. surgery Not stated Rate of recurrence Not stated
ENCLOSURE48) Spain 280 Dec-23 CSDH >10 mm or symptoms MMAE + surgery vs. surgery Onyx, Phil, Squid, or Libro Symptomatic recurrence or radiological 6 months
ELIMINATE44) Netherlands 170 Oct-25 Age ≥50 years, symptoms MMAE + surgery vs. surgery PVA particles Repeat surgery 8, 16, 24 weeks
MEMBRANE (Germany)49) Germany 154 Oct-25 Candidate for surgery MMAE + surgery vs. surgery PVA particles (mainly) Repeat surgery or radiological 3 months
EMPROTECT38) France 342 Oct-23 Recurrence or high risk factor of recurrence MMAE + surgery vs. conventional treatment EmboSphere Repeat surgery or radiological 6 months
EMMA-Can50) Canada 200 Mar-26 Symptoms and mRS score ≤2 MMAE + conventional treatment vs. conventional treatment Particulate polymer or liquid embolic agents Radiological 3 months
COMPLEMENT39) Japan 600 Mar-29 Pre-mRS score ≤3, CSDH ≥10 mm, at least 1 risk factor for recurrence MMAE + conventional treatment vs. conventional treatment Not stated Repeat surgery or radiological 6 months
MMAE vs. surgery or conservative
Embotrial-136) Italy 300 Mar-26 Markwalder grade ≤1 MMAE vs. conservative management PVA particles or liquid embolic agents Requires surgery or hematoma resolution 6 months
SWEMMA34) Sweden 288 Mar-27 Markwalder grade <2, GCS >13 MMAE vs. surgery Onyx, Squid, or Phil Repeat surgery 3 months
CHESS33) USA 520 Feb-29 Age ≥40 years, CSDH >10 mm MMAE vs. surgery EmboSphere or Contour Repeat surgery or death 6–7 months
PREMMA35) Puerto Rico 658 Jul-32 Markwalder grade ≤2, GCS ≥14 MMAE vs. surgery PVA particles Repeat surgery 3, 6, 12 months

Contour, Boston Scientific, Marlborough, MA, USA; CSDH, chronic subdural hematoma; Embosphere, Merit Medical, South Jordan, UT, USA; GCS, Glasgow Coma Scale; Libro, INVAMED, Ankara, Turkey; MMAE, middle meningeal artery embolization; mRS, modified Rankin Scale; n-BCA, N-butyl-2-cyanoacrylate; Onyx, Medtronic, Irvine, CA, USA; PHIL, Terumo Neuro, Aliso Viejo, CA, USA; PVA, polyvinyl acrylate; Squid, Balt, Montmorency, France; TRUFILL, Johnson & Johnson, Irvine, CA, USA